Tags

Type your tag names separated by a space and hit enter

Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial.
Muscle Nerve. 2007 Jan; 35(1):66-9.MN

Abstract

We studied the effect of rituximab in allowing a reduction in dose of intravenous immune globulin (IVIg) in six patients with IVIg-dependent, relapsing immune polyneuropathy. Rituximab (375 mg/m(2) intravenously each week for 4 weeks) was administered in a prospective, open-label design to two patients with chronic inflammatory demyelinating polyneuropathy (CIDP), two with multifocal motor neuropathy (MMN), one with neuropathy and anti-myelin-associated glycoprotein (MAG) antibody neuropathy, and one with Sjögren syndrome (SS) ataxic neuropathy. The primary endpoint was a reduced cumulative IVIg dosage by at least 25% at 1 year after rituximab therapy compared to the previous year. Secondary endpoints included an improved summed strength score by at least 5 points on the Medical Research Council scale, an increased sensory score by at least 4 points, or an improved Rankin disability score by at least 1 grade. Total IVIg dosage decreased by greater than 25% in one patient with SS neuropathy and one with MMN; the dosage was unchanged in one with CIDP, slightly reduced in the patient with anti-MAG neuropathy, and increased in one with CIDP and another with MMN. There was no improvement in secondary endpoints. No adverse events occurred. In this small prospective study, rituximab did not reduce IVIg requirements in the majority of patients with IVIg-dependent, immune-mediated polyneuropathies.

Authors+Show Affiliations

Department of Neurology, Caritas St. Elizabeth's Medical Center, Tufts University School of Medicine, 736 Cambridge Street, Boston, Massachusetts 02135, USA. kengorson@comcast.netNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

16967492

Citation

Gorson, Kenneth C., et al. "Rituximab Treatment in Patients With IVIg-dependent Immune Polyneuropathy: a Prospective Pilot Trial." Muscle & Nerve, vol. 35, no. 1, 2007, pp. 66-9.
Gorson KC, Natarajan N, Ropper AH, et al. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve. 2007;35(1):66-9.
Gorson, K. C., Natarajan, N., Ropper, A. H., & Weinstein, R. (2007). Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle & Nerve, 35(1), 66-9.
Gorson KC, et al. Rituximab Treatment in Patients With IVIg-dependent Immune Polyneuropathy: a Prospective Pilot Trial. Muscle Nerve. 2007;35(1):66-9. PubMed PMID: 16967492.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. AU - Gorson,Kenneth C, AU - Natarajan,Neela, AU - Ropper,Allan H, AU - Weinstein,Robert, PY - 2006/9/13/pubmed PY - 2007/2/28/medline PY - 2006/9/13/entrez SP - 66 EP - 9 JF - Muscle & nerve JO - Muscle Nerve VL - 35 IS - 1 N2 - We studied the effect of rituximab in allowing a reduction in dose of intravenous immune globulin (IVIg) in six patients with IVIg-dependent, relapsing immune polyneuropathy. Rituximab (375 mg/m(2) intravenously each week for 4 weeks) was administered in a prospective, open-label design to two patients with chronic inflammatory demyelinating polyneuropathy (CIDP), two with multifocal motor neuropathy (MMN), one with neuropathy and anti-myelin-associated glycoprotein (MAG) antibody neuropathy, and one with Sjögren syndrome (SS) ataxic neuropathy. The primary endpoint was a reduced cumulative IVIg dosage by at least 25% at 1 year after rituximab therapy compared to the previous year. Secondary endpoints included an improved summed strength score by at least 5 points on the Medical Research Council scale, an increased sensory score by at least 4 points, or an improved Rankin disability score by at least 1 grade. Total IVIg dosage decreased by greater than 25% in one patient with SS neuropathy and one with MMN; the dosage was unchanged in one with CIDP, slightly reduced in the patient with anti-MAG neuropathy, and increased in one with CIDP and another with MMN. There was no improvement in secondary endpoints. No adverse events occurred. In this small prospective study, rituximab did not reduce IVIg requirements in the majority of patients with IVIg-dependent, immune-mediated polyneuropathies. SN - 0148-639X UR - https://www.unboundmedicine.com/medline/citation/16967492/Rituximab_treatment_in_patients_with_IVIg_dependent_immune_polyneuropathy:_a_prospective_pilot_trial_ L2 - https://doi.org/10.1002/mus.20664 DB - PRIME DP - Unbound Medicine ER -